$KOD News

Kodiak Sciences Files Shelf Prospectus For Offering; Size Not Disclosed

HC Wainwright & Co. Maintains Buy on Kodiak Sciences, Raises Price Target to $126

Kodiak Sciences Inc. (KOD) Presents at American Academy of Ophthalmology Conference 2026 - Slideshow

Kodiak Sciences (KOD) Could Be 7% Overvalued Following Late Stage Data Update

Kodiak Sciences (KOD) Stock Trades At A Premium On DAYBREAK Trial News

Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026

Kodiak Sciences’ Two Wet AMD Treatments Match Aflibercept in Phase III Study

This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking

Kodiak Sciences More Than Doubles on Eye Disease Trial Results

What Does Regeneron Pharmaceuticals (REGN) Need To Prove In Eye Disease Now?

Kodiak Sciences (KOD) Climbs Nearly 3x on Promising Wet AMD Trial

Why This Regeneron Eye Rival Just Catapulted More Than 120%

Inside the Eye-Drug Breakthrough That Sent Kodiak Sciences Up 172%

Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary endpoints in phase III wet AMD trial

Kodiak skyrockets on positive study data for 2 eye drugs

Kodiak’s stock rallies on Phase III wAMD success

Kodiak Sciences Soars 141% on “Truly Impressive” Pivotal Wet AMD Trial Win

Kodiak Stock Soars (Again) As Data Shows Long-Lasting Eye Meds Are 'Real Deal'

This Biotech Company Added Nearly $3B To Its Market Cap – Here’s Why KOD Stock Is Ripping Today

Kodiak Sciences Inc. (KOD) Discusses DAYBREAK Topline Data and Primary Endpoint Results Transcript